Photo by schluditsch from unsplash
This article presents the efficacy of co‐amoxiclav in two patients with ankylosing spondylitis. Both patients were administered oral co‐amoxiclav for 7 days. The primary efficacy variable was the ankylosing spondylitis… Click to show full abstract
This article presents the efficacy of co‐amoxiclav in two patients with ankylosing spondylitis. Both patients were administered oral co‐amoxiclav for 7 days. The primary efficacy variable was the ankylosing spondylitis activity index. Secondary outcome measures were the ankylosing spondylitis functional index and spinal mobility. We detected a marked improvement in all symptoms and physical examination parameters. Co‐amoxiclav has been shown to be effective against ankylosing spondylitis.
Keywords:
spondylitis amoxiclav;
ankylosing spondylitis;
treatment ankylosing;
pharmacology;
spondylitis
Journal Title: Clinical and Experimental Pharmacology and Physiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical and Experimental Pharmacology and Physiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!